Does urinary D-arabinitol reflect Candida metabolic activity even when stool PCR counts are low?

Urinary D-arabinitol serves as an established, sensitive biomarker for Candida metabolic activity. It reflects systemic and mucosal fungal burden independently of localized stool PCR findings, which only capture lower gastrointestinal shedding.

Biochemical pathways and renal excretion

• Metabolic synthesis: Pathogenic Candida species (specifically C. albicans) synthesize D-arabinitol from glucose via the oxidative pentose phosphate pathway. Glucose is converted to D-ribulose-5-phosphate, dephosphorylated to D-ribulose, and reduced to D-arabinitol.
• Renal clearance: Once synthesized, this five-carbon sugar alcohol enters the bloodstream and is excreted in urine. Because kidney function modulates excretion, clinical assessments normalize levels to creatinine or utilize the D-arabinitol to L-arabinitol (DA/LA) ratio to ensure diagnostic accuracy.

Clinical divergence from stool PCR

• Compartmentalization: Urinary D-arabinitol reflects the overall systemic and mucosal metabolic burden across multiple anatomical sites, including the oral cavity, upper gastrointestinal tract, and vaginal mucosa.
• Diagnostic discordance: Conversely, stool PCR specifically quantifies localized fungal DNA within the lower intestinal lumen. Consequently, urinary D-arabinitol can elevate during active, non-intestinal mucosal colonization or tissue invasion even when stool PCR counts remain normal. Concordance between these biomarkers typically increases only during high-burden, invasive candidiasis.

Bottom line

• Urinary D-arabinitol is a validated marker of systemic and mucosal Candida metabolic activity that can elevate independently of stool PCR counts due to anatomical compartmentalization and systemic absorption.